Efficacy and safety of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Entrectinib▼ is a tyrosine kinase inihbitor approved globally for the treatment of NTRK fusion-positive solid tumours, based on the results of three phase 1/2 trials (ALKA-372-001; STARTRK-1; STARTRK-2).
Updated results (enrolment cut-off: 31 Jul 2019; clinical cut-off 31 Aug 2020) are presented.
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
We use cookies and other technologies (“cookies”) to improve our website. Besides the strictly necessary cookies, we would like to use cookies (1) to learn how our website is used and how it performs, including cross-site statistics, (2) to provide you with additional functionalities and personalisation (3) to provide you social media interactions and (4) for targeting and marketing purposes. By clicking “Accept all”, you consent to the use of all cookies and the corresponding data processing which may include your browser-information and IP-address as well as the disclosure of personal data to third parties as further described in our Cookie/Privacy Policy. For more information, configuration and to withdraw your consent, please click “Cookie Preferences”.Cookie Notice.